The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease: a systematic review and meta-analysis

Purpose In recent years, increasing evidence has shown that sodium-glucose cotransporter 2 inhibitors (SGLT2i) drugs have potential renoprotective effects in patients with diabetes mellitus (DM). However, the renal protective effect of SGLT2i in non-diabetic nephropathy patients has not been extensi...

Full description

Saved in:
Bibliographic Details
Published in:International urology and nephrology 2023-12, Vol.55 (12), p.3167-3174
Main Authors: Ma, Congyuan, Li, Xuanwei, Li, Wenlai, Li, Yue, Shui, Fangfang, Zhu, Ping
Format: Article
Language:English
Subjects:
Blood pressure
Clinical trials
Creatinine
Diabetes
Diabetes mellitus
Diabetic nephropathy
Epidermal growth factor receptors
Glomerular filtration rate
Kidney diseases
Medicine
Medicine & Public Health
Meta-analysis
Nephrology
Nephrology - Original Paper
Nephropathy
Patients
Sodium-glucose cotransporter
Systematic review
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose In recent years, increasing evidence has shown that sodium-glucose cotransporter 2 inhibitors (SGLT2i) drugs have potential renoprotective effects in patients with diabetes mellitus (DM). However, the renal protective effect of SGLT2i in non-diabetic nephropathy patients has not been extensively demonstrated. In this systematic review and meta-analysis, we aimed to evaluate the renal protective effect and safety of SGLT2i in non-diabetic nephropathy patients. Methods we searched for relevant clinically randomised controlled trials and analyzed the effects of SGLT2i on estimated glomerular filtration rate (eGFR), urinary albumin/creatinine ratio (UACR), and systolic blood pressure (SBP) and the incidence of adverse events in patients with non-diabetic nephropathy. Results We collated and analysed clinical data from six groups of patients with nondiabetic nephropathy. It was found that the SGLT2i significantly delayed the decline in eGFR [MD = 1.35 ml/min/1.73 m 2 , 95% CI 0.84, 1.86), P  
ISSN:1573-2584
0301-1623
1573-2584
DOI:10.1007/s11255-023-03586-1